Barclays Maintains an 'Overweight' on Onyx Pharmaceuticals (ONXX); Amended CFZ Deal Provides Incentive for Timely Filing
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Onyx Pharmaceuticals (NASDAQ: ONXX), PT $42.
Barclays analyst says, "ONXX reported late yesterday in an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "ONXX reported late yesterday in an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
